The China NMPA grants Priority Review to Nefecon’s NDA for the treatment of primary IgA nephropathy in adults at risk of rapid disease progression
In Nov 2022, the NMPA accepted NDA and also granted BTD for the same indication. Nefecon, a delayed-release capsule containing coated beads of budesonide that targets mucosal B-cells in the ileum
In Jun 2019, from a royalty-bearing license agreement with Calliditas, Everest Medicines gains exclusive rights for the development and commercialization of Nefecon in Mainland China, Hong Kong, Macau, Taiwan, and Singapore which later extended to South Korea in Mar 2022
Ref: PR Newswire | Image: Everest Medicines
Related News:- Everest Medicines Expands its 2019 Collaboration with Calliditas to Develop and Commercialize Nefecon for Primary IgA Nephropathy in South Korea
